Release date: December 1, 2006
(Accreditation Expired)
Program Description
Schizophrenia is a major mental illness, affecting approximately 2.4 million American adults. It is also among the world’s top ten causes of long-term disability. The availability of antipsychotic drugs to treat schizophrenia has greatly expanded with the addition of several newer agents, and it is therefore important for clinicians to be able to compare these agents with regard to long-term efficacy and safety. This program focuses on several recent clinical trials in hopes of providing doctors with information to help guide the selection of anti-psychotic medications for patients with schizophrenia. This educational activity is designed to help interpret the findings of these trials and assist physicians faced with the common and confusing dilemma of choosing an antipsychotic agent that will produce the most positive outcomes for their patients with schizophrenia.
Target Audience
This program is intended for psychiatrists and other healthcare providers who care for patients with schizophrenia or other chronic mental illness.
Educational Objectives
Upon completion of this educational activity participants will be able to:
Discuss the rationale for the initiation of major clinical trials in schizophrenia, including CATIE, CAFÉ, and others
Interpret the results of these important trials and discuss the applications of the results of these trials to clinical practice
Assess and compare the safety, efficacy and side effect profiles of various antipsychotics (conventional and atypical)
Understand the importance of providing individualized treatment strategies for patients with schizophrenia.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint-sponsorship of the University of California, Irvine School of Medicine and Scinexa. The University of California Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
The University of California, Irvine School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure Policy
It is the policy of the University of California, Irvine School of Medicine and the University of California CME Consortium to ensure balance, independence, objectivity and scientific rigor in all CME activities. All presentations have been peer reviewed for evidence-base and fair balance.
Individual Disclosure Statements
Dr. Stroup disclosed that he is a member of the speakers bureau and consultant for Lilly and Pfizer and a consultant for Janssen, which could be perceived as a potential conflict of interest in his presentation. Dr. Stroup further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation.
Dr. McEvoy disclosed that he is a grant/research support recipient for AstraZeneca and is a grant/research support recipient and honoraria recipient for Bristol-Myers Squibb, Janssen, Lilly and Pfizer, which could be perceived as a potential conflict of interest in his presentation. Dr. McEvoy further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation.
Dr. Citrome disclosed that he is a member of the speakers' bureau, grant/research support recipient, consultant, and stock holder for Eli Lilly and Pfizer; a speakers' bureau and grant/research support recipient for Pfizer; a grant/research support recipient and stockholder for Janssen and Bristol-Myers Squibb; a member of the speakers' bureau and stockholder for Abbott Laboratories; a grant/research support recipient for Barr Laboratories; a consultant for Jazz Pharmaceuticals; a consultant and stockholder for GlaxoSmithKline; and a stockholder for Merck, which could be perceived as a potential conflict of interest in his presentation. Dr. Citrome further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation.
Resolution
All materials have been reviewed for evidence base and fair balance.
Staff Disclosure Declarations
The employees of Scinexa Medical Education Company and ArcMesa Educators have no financial relationships to disclose.
Printer settings may vary. Please use landscape layout option.
Scott Stroup, MD, MPH
Associate Professor of Psychiatry
Adjunct Associate Professor of Social Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Faculty
Joseph McEvoy, MD
Associate Professor of Psychiatry
Behavioral Sciences
Duke University Medical Center
Deputy Clinical Director
John Umstead Hospital
Butner, NC
Leslie Citrome, MD, MPH
Director, Clinical Research and Evaluation Facility
Nathan S Kline Institute for Psychiatric Research
Professor of Psychiatry
New York University School of Medicine
Orangeburg, NY
The University of California, Irvine School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
